Liposomal daunorubicin (DaunoXome) in multiple myeloma: A modified VAD regimen using short-term infusion

Anti-Cancer Drugs

Volumn 14, Issue 10, 2003, Pages 793-799

  Eucker, Jan ^a   Eikel, Daniel ^b   Heider, Ulrike ^a   Jakob, Christian ^a   Zavrski, Ivana ^a   Gatz, Frauke ^a   Mergenthaler, Hans Günther ^a   Jungclas, Hartmut ^c   Possinger, Kurt ^a   Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Liposomal daunorubicin; Multiple myeloma; Pharmacokinetics

Indexed keywords

DAUNORUBICIN; DEXAMETHASONE; VINCRISTINE;

ADULT; AGED; ALLERGY; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERANCE; FEMALE; HEART DISEASE; HUMAN; INFECTION; KIDNEY DISEASE; MALE; MAXIMUM TOLERATED DOSE; MEDICAL ASSESSMENT; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REDUCTION; REMISSION; SHORT COURSE THERAPY; SKIN DISEASE;

EID: 12144288071     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200311000-00004     Document Type: Article

References (30)

1. Sezer O, Heider U, Zavrski I, Kühne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101:2094-2098.
2. Niemöller K, Jakob C, Heider U, et al. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III. J Cancer Res Clin Oncol 2003; 129:234-238.
3. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of NF-κB ligand (RANKL) on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003; 9:1436-1440.
4. Jakob C, Zavrski I, Heider U, et al. Serum levels of carboxy-terminal telopeptide of type-I collagen (ICTP) are elevated in patients with multiple myeloma showing skeletal manifestations in magnetic resonance imaging but lacking lytic bone lesions in conventional radiography. Clin Cancer Res 2003; 9:3047-3051.
5. Zavrski I, Naujokat C, Niemöller K, et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003; 129:383-391.
6. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
7. Stead ML, Brown JM, Velikova G, et al. Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. Br J Haematol 1999; 104:605-611.
8. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984; 310: 1353-1356.
9. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of Intergroupe Francophone du Myélome 9502 randomized trial. Blood 2002; 99:731-735.
10. Palumbo A, Triolo S, Argentino C, et al. Dose intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94:1248-1253.
11. Barlogie B, Jagannath S, Vesole DH, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89:789-793.
12. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Ass 1991; 266:1672-1677.
13. Forssen EA. The design and development of DaunoXome® for solid tumor targeting in vivo. Adv Drug Deliv Rev 1997; 24:133-150.
14. Forssen EA, Ross ME. DaunoXome treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 1994; 4:481-512.
15. Salmon SE, Durie BGM. A clinical staging system for multiple myeloma. Cancer 1975; 36:842-854.
16. Bellott R, Pouna P, Robert J. Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with daunoxome. J Chrom B 2001; 757:257-267.
17. Mohrbacher AF, Gregory SA, Gabriel DA, Rusk JM, Giles FJ. Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. Cancer 2002; 94:2645-2652.
18. Richardson DS, Kelsey SM, Johnson SA, et al. Early evaluation of liposomal daunorubicin (DaunoXome, Nextar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs 1997; 15:247-253.
19. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13:996-1003.
20. Fassas A, Buffels R, Anagnostopoulos A, et al. Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study. Br J Haematol 2002; 116:308-315.
21. Flinn D, Goodman SN, Post L, et al. A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. Ann Oncol 2000; 11:691-695.
22. Cortes J, O'Brian S, Estey E, et al. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs 1999; 17:81-87.
23. Pratt G, Wiles ME, Rawstron AC, et al. Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma. Hematol Oncol 1998; 16:47-55.
24. Oivanen TM, Kellokumpu-Lehtinen P, Koivisto AM, Koivonen E, Palva I for the Finnish Leukaemia Group. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol 1999; 62:109-116.
25. Browman GP, Belch A, Skillings J, et al. Modified adriamycin-vincristine- dexamethasone (mVAD) in primary refractory and relapsed plasma cell myeloma: an NCI (Canada) pilot study. Br J Haematol 1992; 82:555-559.
26. Koskela K, Pelliniemi TT, Remes K. VAD regimen in the treatment of resistant multiple myeloma: slow or fast infusion? Leuk Lymph 1993; 10:347-351.
27. Hussein MA, Wood L, Hsi E, et al. A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 2002; 95:2160-2168.
28. Tsiara SN, Kapsali E, Christou L, et al. Administration of modified chemotherapy regimen containing vincristine, liposomal doxorubicin and dexamethasone to multiple myeloma patients: preliminary data. Eur J Haematol 2000; 65:118-122.
29. Gray A, Landfair DJ, Wiles ME. Cellular uptake of liposomal daunorubicin and the induction of apoptosis. Drug Deliv 1999; 6:213-226.
30. Zucchetti M, Boiardi A, Silvani A, et al. Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. Cancer Chemother Pharmacol 1999; 44:173-176.